J Korean Med Sci.  2016 May;31(5):824-824. 10.3346/jkms.2016.31.5.824.

Letter to the Editor: Should We Really Take Anti-Viral Therapy into Account in Chronic Hepatitis B Patients with Normal Liver Function?

• Khosravi M
• Alavian SM

• KMID: 2373686
• DOI: http://doi.org/10.3346/jkms.2016.31.5.824

Abstract

No abstract available.

MeSH Terms

Antiviral Agents/*therapeutic use
Hepatitis B virus
Hepatitis B, Chronic/*drug therapy
Humans
Antiviral Agents

Reference

1. Lee J, Sinn DH, Kim JH, Gwak GY, Kim HS, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, et al. Hepatocellular carcinoma risk of compensated cirrhosis patients with elevated HBV DNA levels according to serum aminotransferase levels. J Korean Med Sci. 2015; 30:1618–1624.

2. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008; 103:1663–1673.

3. Vanni E, Bugianesi E. Obesity and liver cancer. Clin Liver Dis. 2014; 18:191–203.

4. Keshvari M, Alavian SM, Sharafi H. How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon. 2014; 14:e15285.

5. Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014; 63:1943–1950.

6. Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, Merza MA, Keshvari M. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state. Diagn Microbiol Infect Dis. 2015; 82:114–119.